Betnesol-N (Betamethasone/Neomycin)
Is It Right for You?
A complete guide to Betnesol-N (Betamethasone/Neomycin) — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Betnesol-N?
Betnesol-N is a combined corticosteroid and antibiotic preparation supplied as eye, ear and nose drops. Each millilitre of solution contains betamethasone sodium phosphate 0.1% (a potent topical corticosteroid) and neomycin sulphate 0.5% (an aminoglycoside antibiotic). The combination provides simultaneous anti-inflammatory action and antibacterial cover, which is useful in inflammatory conditions of the eyes, ears, or nose where bacterial infection is present, suspected, or likely to develop.
Betnesol-N drops are most commonly used short term — typically up to 7 days — for conditions such as allergic conjunctivitis with secondary bacterial infection, blepharoconjunctivitis, otitis externa, and certain inflammatory nasal conditions where bacterial cover is appropriate. The same bottle can be used in eyes, ears, and nose, though the typical dosing differs by site of application.
Betnesol-N is a prescription-only medication in the UK. A licensed clinician must confirm the diagnosis, exclude viral or fungal infection (which would be worsened by the corticosteroid), check for contraindications such as a perforated eardrum, and review the treatment site, duration, and dose before prescribing.
What Conditions Is Betnesol-N Used For?
Betnesol-N is prescribed short term for inflammatory conditions of the eye, ear, or nose where bacterial infection is also present, suspected, or likely:
Betnesol-N drops are used for short-term treatment of inflammatory eye conditions where bacterial infection is present, suspected, or likely. Indications include allergic and other forms of conjunctivitis, blepharitis, blepharoconjunctivitis, and inflammatory conditions after eye surgery. The combination of betamethasone (corticosteroid) with neomycin (antibiotic) controls both the inflammatory response and bacterial overgrowth.
Used in the management of otitis externa (inflammation of the outer ear canal) where bacterial infection accompanies or complicates the underlying eczematous or inflammatory process. Betamethasone reduces the inflammation, swelling, and discomfort, while neomycin provides antibacterial cover against common ear pathogens.
Betnesol-N drops can be used short term in the nose for inflammatory rhinitis where bacterial infection is suspected or present — although in current UK practice, nasal use is less common, with most patients now managed with targeted nasal corticosteroid sprays or topical antibiotics as appropriate.
Topical anti-inflammatory and antibacterial cover for the eye in the immediate post-operative period (for example after cataract surgery), where the combination of inflammation control and prophylactic antibacterial cover is required. Use should be guided by the operating surgeon.
Betnesol-N must not be used in undiagnosed red eye, viral, fungal, or mycobacterial eye infections, or in a perforated eardrum unless specifically directed by a clinician. The corticosteroid component can mask infection and cause significant damage in these settings — including corneal scarring, visual loss, and (with ear use in perforated drums) irreversible hearing loss from neomycin. Diagnostic accuracy before prescribing is essential.
How Does Betnesol-N Work?
Betnesol-N combines two active ingredients with complementary mechanisms targeting inflammation and bacterial infection:
Betamethasone sodium phosphate (potent topical corticosteroid): Betamethasone is a synthetic fluorinated glucocorticoid that diffuses across cell membranes to bind intracellular glucocorticoid receptors. The receptor-ligand complex translocates to the nucleus where it modulates gene transcription, suppressing the production of pro-inflammatory cytokines (interleukins, tumour necrosis factor), reducing leukocyte migration and accumulation at the site of inflammation, stabilising lysosomal and capillary membranes, and inhibiting phospholipase A2 — thereby reducing prostaglandin and leukotriene synthesis. The net effect is rapid reduction of inflammation, swelling, redness, and itching. Betamethasone is classified as a potent corticosteroid and has both genomic (slower, transcriptional) and non-genomic (rapid, membrane-mediated) actions.
Neomycin sulphate (aminoglycoside antibiotic): Neomycin binds irreversibly to the 30S subunit of bacterial ribosomes, disrupting protein synthesis and producing bactericidal activity against a wide range of Gram-positive and Gram-negative organisms commonly responsible for superficial eye, ear, and nasal infections. Importantly, neomycin has poor activity against Pseudomonas, Streptococcus pyogenes, and anaerobes — a clinically relevant gap that influences when it is the right choice. Topical application limits systemic absorption, though significant local absorption can occur particularly through the ear canal in inflamed or perforated states.
Combined action: The combination simultaneously suppresses the inflammatory response (rapid symptom relief) and provides antibacterial cover (treating or preventing secondary bacterial infection). This dual action makes Betnesol-N particularly useful in inflammatory conditions of the eye, ear, and nose where bacterial colonisation or infection is contributing to the clinical picture.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Wash and dry your hands before instilling the drops. Tilt your head back, gently pull down the lower eyelid (for eye drops) or lie on your side with the affected ear uppermost (for ear drops). Avoid letting the dropper tip touch your eye, ear, or any other surface to prevent contamination of the solution.
For eye drops: instil 1–2 drops into the affected eye(s) as prescribed. Close your eye gently for 1–2 minutes after each dose and press lightly on the inner corner of the eye to reduce systemic absorption.
For ear drops: warm the bottle in your hand for a few minutes before use to avoid a cold sensation. After instilling the drops, remain on your side for several minutes to allow the drops to reach the affected area.
For nose drops: tilt your head back, instil 2–3 drops into each nostril, and remain in that position for about a minute.
Do not use Betnesol-N for longer than 7 days without clinical review. Prolonged use risks raised intraocular pressure, cataract formation, and (with ear use) irreversible hearing loss from the neomycin component.
Remove soft contact lenses before instilling eye drops and wait at least 15 minutes before reinserting them. Many clinicians advise avoiding lens wear altogether during the treatment course.
Discard the bottle 4 weeks after opening, even if there is medication left, to reduce the risk of microbial contamination.
Side Effects of Betnesol-N
Most side effects are mild and local, but serious side effects can occur particularly with prolonged use or in vulnerable patients.
- Burning, stinging, or temporary blurred vision after instillation (eye drops)
- Local irritation or itching
- Mild redness
- Unpleasant taste in the back of the throat (nasal drops)
- Headache
- Irreversible partial or total deafness — a known risk of the neomycin component, particularly with use in the ear, with prolonged or extensive treatment, or in patients with renal impairment
- Raised intraocular pressure and steroid-induced glaucoma — particularly with prolonged eye use or in those with pre-existing glaucoma risk
- Posterior subcapsular cataract — with prolonged ocular corticosteroid use
- Worsening of undiagnosed or untreated infection — the steroid can mask and accelerate viral, fungal, or mycobacterial infections, sometimes causing serious or permanent damage to the eye
- Adrenal suppression — with extensive or prolonged use, particularly nasal use over large areas
- Severe hypersensitivity reactions — anaphylaxis or contact sensitisation to neomycin (relatively common) or to betamethasone
- Emergence of resistant organisms — with prolonged antibiotic exposure
- Corneal thinning or perforation — in eyes with pre-existing corneal pathology
The most clinically important risk of Betnesol-N — particularly when used in the ear — is irreversible hearing loss from the neomycin component. The risk is dose-related and significantly increased in patients with a perforated eardrum, in those with renal or hepatic impairment, and with prolonged use. Ear drops should be used for no longer than 7 days without specialist review, and must not be used in a perforated eardrum unless specifically directed by a clinician with full awareness of the risks.
Drug Interactions
Although Betnesol-N drops are applied topically, both betamethasone and neomycin are absorbed in small amounts and can cause clinically important interactions in specific circumstances. Always disclose all prescription medications, over-the-counter medicines, vitamins, and supplements to your clinician or pharmacist before starting treatment.
Strong inhibitors of cytochrome P450 3A4 — including ritonavir-boosted antiretrovirals and cobicistat-containing HIV regimens — can substantially increase systemic exposure to betamethasone if absorption from topical use is significant, raising the risk of systemic corticosteroid effects such as Cushingoid features and adrenal suppression. The combination should be avoided unless clinically necessary, with appropriate monitoring.
Concurrent use with other aminoglycoside antibiotics (gentamicin, tobramycin, amikacin) given by any route can increase the cumulative risk of nephrotoxicity and ototoxicity, including irreversible hearing loss — particularly with prolonged ear or nasal use of Betnesol-N where some systemic absorption occurs, and in patients with renal impairment.
Betnesol-N drops contain benzalkonium chloride as a preservative, which is absorbed by soft contact lenses and can cause irritation and lens discolouration. Soft contact lenses must be removed before instilling the drops and not reinserted for at least 15 minutes afterwards, or avoided entirely during the treatment course.
Concurrent use of other topical or systemic corticosteroids increases cumulative corticosteroid exposure and the risk of systemic effects including HPA-axis suppression, particularly with prolonged or extensive use.
Important Warnings
Neomycin is an aminoglycoside antibiotic associated with a small but real risk of irreversible partial or total deafness (ototoxicity), particularly when used in the ear, with prolonged or extensive use, or in patients with renal or hepatic impairment. Ear drops should not be used for more than 7 days without specialist review and should be avoided in patients with a perforated tympanic membrane unless specifically directed.
Betnesol-N eye drops must not be used in undiagnosed red eye, suspected herpes simplex (dendritic) keratitis, fungal eye infections, mycobacterial eye infections, or other primary viral ocular infections. Topical corticosteroids in these conditions can cause significant and sometimes irreversible damage to the eye, including corneal scarring and visual loss.
Prolonged use of topical corticosteroid eye drops can raise intraocular pressure and cause steroid-induced glaucoma, particularly in patients with pre-existing glaucoma or a family history. Long-term use can also accelerate cataract formation. Use should be short term, with intraocular pressure monitored if longer courses are required.
Ear drops should be avoided in patients with a perforated tympanic membrane (eardrum) unless specifically directed by a clinician, because of the increased risk of neomycin reaching the inner ear and causing ototoxicity. If you have ear pain, discharge, or hearing loss, your clinician will need to examine the ear before prescribing.
Betnesol-N drops contain benzalkonium chloride as a preservative. They must not be instilled while wearing soft contact lenses, as the preservative is absorbed by the lens and can cause irritation and discoloration. Soft lenses should be removed before use and not reinserted for at least 15 minutes.
Safety in pregnancy and breastfeeding has not been fully established. Topical corticosteroids can theoretically cause foetal harm at higher exposures. Use during pregnancy or breastfeeding should be confined to circumstances where the clinical benefit clearly outweighs the theoretical risk, at the lowest effective dose for the shortest time.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Betnesol-N FAQs
Betnesol-N is a combination preparation containing two active ingredients: betamethasone sodium phosphate 0.1% (a corticosteroid that reduces inflammation, swelling and itch) and neomycin sulphate 0.5% (an antibiotic that treats or prevents bacterial infection). It is supplied as drops that can be used in the eyes, ears, or nose for inflammatory conditions where bacterial infection is present, suspected, or likely.
For the eyes, the usual dose is 1–2 drops every 1–2 hours during the acute phase, reducing to 3–4 times daily once inflammation improves. For ears and nose, the usual dose is 2–3 drops 2–3 times daily. Always follow the specific dose your clinician has prescribed and do not exceed 7 days of treatment without clinical review.
Betnesol-N should not be used for more than 7 days without clinical review. The combination of a potent corticosteroid with an aminoglycoside antibiotic carries small but real risks of raised eye pressure, cataract formation, and (in the ear) hearing loss with prolonged use. If your symptoms have not improved after 7 days, contact your clinician rather than continuing.
You must remove soft contact lenses before instilling Betnesol-N drops and wait at least 15 minutes before reinserting them. The drops contain benzalkonium chloride, a preservative that is absorbed by soft contact lenses and can cause eye irritation and discoloration of the lens. Many clinicians advise avoiding contact lens wear altogether during the treatment course.
Betnesol-N ear drops should be avoided in patients with a perforated eardrum unless specifically directed by a clinician, because the neomycin antibiotic can reach the inner ear and cause irreversible hearing loss. If you have ear pain, discharge, or hearing loss, your clinician will need to examine your ear before deciding whether Betnesol-N is appropriate.
Betnesol-N drops are not recommended for routine use in pregnancy or breastfeeding unless clearly necessary, as safety has not been fully established. If treatment is essential, the smallest effective dose should be used for the shortest possible time. Always discuss any planned use during pregnancy or breastfeeding with your clinician.
If you forget a dose, take it as soon as you remember unless it is nearly time for the next dose — in which case skip the missed dose and continue with your normal schedule. Do not put in extra drops to make up for the missed dose, as this does not improve efficacy and may increase the risk of side effects.
Yes — the drops can briefly impair your vision after instillation due to blurring and stinging. You should wait until your vision has cleared fully before driving or operating machinery, particularly during the first few minutes after each dose.